
ABBOTT PARK, Ill., Sept. 7 (UPI) -- Abbott said Thursday it filed with U.S. and European regulatory authorities seeking a Crohn's disease use for Humira.
The company filed a supplemental biologics license application with the U.S. Food and Drug Administration and a type 2 variation with the European Medicine Agency for an indication for Humira for the treatment of moderate to severe Crohn's disease.
The filings are based on three trials: CLASSIC I, CHARM, and GAIN.
"Based on our clinical studies, we believe Humira offers promise for patients who suffer from Crohn's disease," said Eugene Sun, Abbott's vice president of global pharmaceutical clinical development.
"Data from three pivotal studies in more than 1,400 patients suggest the potential of Humira to help many Crohn's disease patients meet their treatment goals of achieving and maintaining control of symptoms and improving quality of life," Sun added.
|
|
|
|
|
|
| Additional Health News Stories | |
WASHINGTON, May 27 (UPI) --
President Obama has put U.S. foreign policy on auto-pilot while he concentrates on getting re-elected, a senior Republican senator said Sunday.
|
'Men in Black' leads U.S. box office ... Michelle Obama, daughters see Beyonce ... Lady Gaga cancels Jakarta gig for security ... Madonna asks for pool at Israel venue ... News from United Press International.
|
ANCHORAGE, Alaska, May 27 (UPI) --
A black bear didn't go over a river but went to the woods after scampering through residential and industrial areas of Anchorage, Alaska, police said.
|
To avoid a meltdown in 2006, Ford Motor Co. mortgaged the farm putting up its assets – including its Blue Oval logo, and F-150 pickup and iconic Mustang trademarks – to secure $23.5 billion in credit.
|
| Stories | Photos | People | Comments |
View Caption